Sign in

Nate Gross

Vice President and Equity Research Analyst at Piper Sandler

Nate Gross is a Vice President and Equity Research Analyst at Piper Sandler, specializing in healthcare sector research with a primary focus on coverage of medical technology and diagnostics companies. He analyzes and provides recommendations on firms such as Dexcom, Inari Medical, and Insulet, consistently delivering insightful investment research to institutional clients. Gross began his career in equity research and has advanced to his current role at Piper Sandler, leveraging prior experience gained at other financial firms where he built his analytical expertise. He is FINRA-registered and holds securities industry licenses including the Series 7, 63, 86, and 87.

Nate Gross's questions to Doximity (DOCS) leadership

Question · Q2 2026

Nate Gross asked about Doximity's market share in clinical reference, whether Docs GPT focuses on specific medical specialties or is broad-based, and if Pathway can ingest patient-specific records or cases.

Answer

Jeff Tangney, Co-founder and CEO, stated Doximity doesn't know its market share in clinical reference but respects the long-standing leader. He emphasized Doximity's focus on accurate, peer-reviewed drug reference answers, noting the early stage of their clinical reference presence and the current inability to ingest patient-specific records.

Ask follow-up questions

Fintool

Fintool can predict Doximity logo DOCS's earnings beat/miss a week before the call